This study has two main objectives. The first objective is to study the pharmacokinetics of topical netarsudil administration in the posterior segment of the eye, where netarsudil must exert its effect in order to prevent formation of tractional membranes.
The second objective is to assess the safety profile of topical netarsudil in the pre- and post-operative periods. A secondary objective of the study is to begin to assess signs of efficacy in preventing formation of tractional membranes post-operatively.
Patients > 18 years old
Patients presenting for primary rhegmatogenous retinal detachment repair within 28 days of symptom onset
Patients undergoing vitrectomy or vitrectomy with scleral buckle
Patient unable to give consent
Patient unable to follow-up
Prior history of retinal detachment incisional surgery in presenting eye
Prior history of open globe injury to presenting eye
Massachusetts Eye and Ear Infirmary
Lead sponsor
Massachusetts General Hospital
Sponsor institution